Merck Sharp & Dohme B.V.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 3af3c5a262
Drug names33First applicant · distinct drug namesAcceptance records212First applicant · distinct acceptance numbersUnder-review numbers26First applicant · current under-review listCo-applicant records10Subsequent applicant only · separate count
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.
Drug filings
212 acceptance records as first applicant, grouped into 33 source drug names. Source data as of 2026/11/11 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
No verified English name 44 records · Latest accepted 2026/11/09
Import · 44
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2600104 | Import | 2026/11/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2600103 | Import | 2026/11/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2600075 | Import | 2026/08/19 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600074 | Import | 2026/08/19 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600053 | Import | 2026/06/16 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| JXSS2600052 | Import | 2026/06/16 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| JXSS2600047 | Import | 2026/06/04 | Merck Sharp & Dohme B. V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Lt d | CDE ↗ |
| JXSS2600046 | Import | 2026/06/04 | Merck Sharp & Dohme B. V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Lt d | CDE ↗ |
| JXSS2600033 | Import | 2026/04/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| JXSS2600032 | Import | 2026/04/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| JXSS2600031 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600030 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600029 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600028 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600027 | Import | 2026/04/02 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600026 | Import | 2026/04/02 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600022 | Import | 2026/03/14 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2600021 | Import | 2026/03/14 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500150 | Import | 2025/12/10 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500149 | Import | 2025/12/10 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500095 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500094 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500093 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500092 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500091 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500090 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500089 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500088 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500087 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500086 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500085 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500084 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500083 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500082 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500081 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500080 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500079 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500078 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500077 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500076 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500075 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500074 | Import | 2025/06/12 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500073 | Import | 2025/06/07 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSS2500072 | Import | 2025/06/07 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/11/04
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600596 | Supplement | 2026/11/04 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2600595 | Supplement | 2026/11/04 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2500576 | Supplement | 2025/10/30 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2500575 | Supplement | 2025/10/30 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
Sugammadex Sodium Injection 11 records · Latest accepted 2026/10/20
Import re-registration · 4Supplement · 7
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600271 | Import re-registration | 2026/10/20 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2600270 | Import re-registration | 2026/10/20 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHB2600367 | Supplement | 2026/07/02 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| JYHB2200420 | Supplement | 2022/08/04 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
| JYHB2200419 | Supplement | 2022/08/04 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
| JYHZ2200127 | Import re-registration | 2022/05/27 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; Name not romanized | CDE ↗ |
| JYHZ2200126 | Import re-registration | 2022/05/27 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; Name not romanized | CDE ↗ |
| JYHB2101330 | Supplement | 2021/08/16 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
| JYHB2101329 | Supplement | 2021/08/16 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
| JYHB2101054 | Supplement | 2021/04/23 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
| JYHB2101053 | Supplement | 2021/04/23 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/09/17
Not stated by source · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTS2600144 | Not stated by source | 2026/09/17 | Merck Sharp & Dohme B.V.; Shanghai Hong Cheng Pharma Co., Ltd. romanized | CDE ↗ |
| JTS2600113 | Not stated by source | 2026/07/02 | Merck Sharp & Dohme B.V.; Shanghai Hong Cheng Pharma Co., Ltd. romanized | CDE ↗ |
Caspofungin Acetate for Injection 10 records · Latest accepted 2026/08/03
Import re-registration · 3Supplement · 7
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600185 | Import re-registration | 2026/08/03 | Merck Sharp & Dohme B. V.; FAREVA Mirabel | CDE ↗ |
| JYHB2500609 | Supplement | 2025/11/12 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2500608 | Supplement | 2025/11/12 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2400354 | Supplement | 2024/07/10 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2400316 | Supplement | 2024/06/25 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2400315 | Supplement | 2024/06/25 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHZ2200078 | Import re-registration | 2022/03/15 | Merck Sharp & Dohme B.V.; FAREVA Mirabel; Name not romanized | CDE ↗ |
| JYHZ2200077 | Import re-registration | 2022/03/15 | Merck Sharp & Dohme B.V.; FAREVA Mirabel; Name not romanized | CDE ↗ |
| JYHB2101104 | Supplement | 2021/05/19 | Merck Sharp & Dohme B.V.; Laboratoires Merck Sharp & Dohme Chibret | CDE ↗ |
| JYHB2101103 | Supplement | 2021/05/19 | Merck Sharp & Dohme B.V.; Laboratoires Merck Sharp & Dohme Chibret | CDE ↗ |
Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets 5 records · Latest accepted 2026/07/20
Supplement · 4Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600397 | Supplement | 2026/07/20 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2500267 | Supplement | 2025/05/15 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHZ2500045 | Import re-registration | 2025/03/07 | Merck Sharp & Dohme B.V.; MSD International GmbH; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2500085 | Supplement | 2025/02/22 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2400344 | Supplement | 2024/07/04 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
Doravirine Tablets 6 records · Latest accepted 2026/07/20
Supplement · 5Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600396 | Supplement | 2026/07/20 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2500268 | Supplement | 2025/05/15 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHZ2500044 | Import re-registration | 2025/03/07 | Merck Sharp & Dohme B.V.; MSD International GmbH; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2500084 | Supplement | 2025/02/21 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2400345 | Supplement | 2024/07/04 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2300350 | Supplement | 2023/06/22 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/05/09
Supplement · 2
Temozolomide Capsules 22 records · Latest accepted 2026/04/10
Import re-registration · 8Supplement · 14
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600086 | Import re-registration | 2026/04/10 | Merck Sharp & Dohme B.V.; Orion Corporation; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHZ2600085 | Import re-registration | 2026/04/10 | Merck Sharp & Dohme B.V.; Orion Corporation; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHZ2600084 | Import re-registration | 2026/04/10 | Merck Sharp & Dohme B.V.; Orion Corporation; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHZ2600083 | Import re-registration | 2026/04/10 | Merck Sharp & Dohme B.V.; Orion Corporation; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2400642 | Supplement | 2024/12/12 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400641 | Supplement | 2024/12/12 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400640 | Supplement | 2024/12/12 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400639 | Supplement | 2024/12/12 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400082 | Supplement | 2024/02/08 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400081 | Supplement | 2024/02/08 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400080 | Supplement | 2024/02/08 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHB2400079 | Supplement | 2024/02/08 | Merck Sharp & Dohme B. V.; Orion Corporation | CDE ↗ |
| JYHZ2100615 | Import re-registration | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHZ2100614 | Import re-registration | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHZ2100613 | Import re-registration | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHZ2100610 | Import re-registration | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101372 | Supplement | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101371 | Supplement | 2021/08/30 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101140 | Supplement | 2021/05/26 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101139 | Supplement | 2021/05/26 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101138 | Supplement | 2021/05/26 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
| JYHB2101137 | Supplement | 2021/05/26 | Merck Sharp & Dohme B.V.; Orion Corporation | CDE ↗ |
Letermovir Tablets 14 records · Latest accepted 2026/04/02
Import re-registration · 2Supplement · 12
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600078 | Import re-registration | 2026/04/02 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine); MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHZ2600077 | Import re-registration | 2026/04/02 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine); MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2500648 | Supplement | 2025/11/28 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2500647 | Supplement | 2025/11/28 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2500496 | Supplement | 2025/09/25 | Merck Sharp & Dohme B.V.; MSD International GmbH T/ A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2500495 | Supplement | 2025/09/25 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2500100 | Supplement | 2025/03/04 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2500099 | Supplement | 2025/03/04 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2400558 | Supplement | 2024/10/22 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2400557 | Supplement | 2024/10/22 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2400532 | Supplement | 2024/10/11 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2400531 | Supplement | 2024/10/11 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2200445 | Supplement | 2022/08/15 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
| JYHB2200444 | Supplement | 2022/08/15 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Ballydine) | CDE ↗ |
Letermovir Injection 14 records · Latest accepted 2026/03/26
Import re-registration · 2Supplement · 12
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600066 | Import re-registration | 2026/03/26 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow); MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHZ2600065 | Import re-registration | 2026/03/26 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow); MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2500644 | Supplement | 2025/11/28 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2500643 | Supplement | 2025/11/28 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2500527 | Supplement | 2025/10/14 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2500526 | Supplement | 2025/10/14 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2500102 | Supplement | 2025/03/04 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2500101 | Supplement | 2025/03/04 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2400562 | Supplement | 2024/10/23 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2400561 | Supplement | 2024/10/23 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2400522 | Supplement | 2024/10/09 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2400521 | Supplement | 2024/10/09 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2200447 | Supplement | 2022/08/16 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
| JYHB2200446 | Supplement | 2022/08/16 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Carlow) | CDE ↗ |
No verified English name 4 records · Latest accepted 2025/12/25
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500248 | Import | 2025/12/25 | Merck Sharp & Dohme B.V.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSL2500247 | Import | 2025/12/25 | Merck Sharp & Dohme B.V.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSL2500166 | Import | 2025/09/02 | Merck Sharp & Dohme B.V.; MSD R&D (China) Co. Ltd | CDE ↗ |
| JXSL2500165 | Import | 2025/09/02 | Merck Sharp & Dohme B.V.; MSD R&D (China) Co. Ltd | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/12/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500658 | Supplement | 2025/12/03 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme LLC; ACS DOBFAR S.P.A. | CDE ↗ |
No verified English name 7 records · Latest accepted 2025/08/02
Supplement · 6Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500403 | Supplement | 2025/08/02 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHZ2500016 | Import re-registration | 2025/02/06 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2400434 | Supplement | 2024/08/07 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2300502 | Supplement | 2023/09/02 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2200288 | Supplement | 2022/06/09 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Brinny) | CDE ↗ |
| JYHB2101044 | Supplement | 2021/04/14 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2100180 | Supplement | 2021/03/10 | Merck Sharp & Dohme B.V.; MSD International GmbH T/A MSD Ireland (Brinny) | CDE ↗ |
Posaconazole Enteric-coated Tablets 8 records · Latest accepted 2025/08/02
Supplement · 7Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500399 | Supplement | 2025/08/02 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| JYHB2400433 | Supplement | 2024/08/07 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| JYHB2400381 | Supplement | 2024/07/23 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| JYHB2300729 | Supplement | 2023/12/16 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| JYHZ2300099 | Import re-registration | 2023/02/23 | Merck Sharp & Dohme B.V.; N.V. Organon; Name not romanized | CDE ↗ |
| JYHB2200482 | Supplement | 2022/09/04 | Merck Sharp & Dohme B.V.; N.V.Organon | CDE ↗ |
| JYHB2200261 | Supplement | 2022/05/11 | Merck Sharp & Dohme B.V.; N.V.Organon | CDE ↗ |
| JYHB2100138 | Supplement | 2021/02/11 | Merck Sharp & Dohme B.V.; N.V.Organon | CDE ↗ |
No verified English name 2 records · Latest accepted 2025/06/06
Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2500071 | Import | 2025/06/06 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2500042 | Import | 2025/04/02 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2025/05/15
Supplement · 1Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500269 | Supplement | 2025/05/15 | Merck Sharp & Dohme B.V.; Steri-Pharma LLC | CDE ↗ |
| JXHS2300107 | Import | 2023/11/25 | Merck Sharp & Dohme B.V.; Steri-Pharma LLC; Name not romanized | CDE ↗ |
| JXHS2300106 | Import | 2023/11/25 | Merck Sharp & Dohme B.V.; Steri-Pharma LLC; Name not romanized | CDE ↗ |
| JXHS2300105 | Import | 2023/11/25 | Merck Sharp & Dohme B.V.; Steri-Pharma LLC; Name not romanized | CDE ↗ |
Sitagliptin Phosphate Tablets 9 records · Latest accepted 2025/03/06
Supplement · 7Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500115 | Supplement | 2025/03/06 | Merck Sharp & Dohme B.V.; Organon Pharma (UK) Limited | CDE ↗ |
| JYHZ2200305 | Import re-registration | 2022/11/02 | Merck Sharp & Dohme B.V.; Organon Pharma (UK) Limited; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2200304 | Import re-registration | 2022/11/02 | Merck Sharp & Dohme B.V.; Organon Pharma (UK) Limited; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHB2101130 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
| JYHB2101129 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
| JYHB2101128 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
| JYHB2101127 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
| JYHB2101126 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
| JYHB2101125 | Supplement | 2021/05/24 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Ltd. | CDE ↗ |
Ertugliflozin Tablets 4 records · Latest accepted 2024/10/11
Import re-registration · 1Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400270 | Import re-registration | 2024/10/11 | Merck Sharp & Dohme B.V.; Pfizer Manufacturing Deutschland GmbH; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHB2400450 | Supplement | 2024/08/15 | Merck Sharp & Dohme B.V.; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2200192 | Supplement | 2022/04/11 | Merck Sharp & Dohme B.V.; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2101055 | Supplement | 2021/04/23 | Merck Sharp & Dohme B.V.; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
Ertapenem For Injection 7 records · Latest accepted 2024/06/22
Import re-registration · 2Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400166 | Import re-registration | 2024/06/22 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHZ2400165 | Import re-registration | 2024/06/22 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2300610 | Supplement | 2023/10/26 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2300609 | Supplement | 2023/10/26 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2200550 | Supplement | 2022/10/12 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2101213 | Supplement | 2021/07/05 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| JYHB2101212 | Supplement | 2021/07/05 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
Aprepitant Capsules 5 records · Latest accepted 2023/11/02
Import re-registration · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300420 | Import re-registration | 2023/11/02 | Merck Sharp & Dohme B.V.; Alkermes Pharma Ireland Ltd.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2300419 | Import re-registration | 2023/11/02 | Merck Sharp & Dohme B.V.; Alkermes Pharma Ireland Ltd.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2300418 | Import re-registration | 2023/11/02 | Merck Sharp & Dohme B.V.; Alkermes Pharma Ireland Ltd.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2300417 | Import re-registration | 2023/11/02 | Merck Sharp & Dohme B.V.; Alkermes Pharma Ireland Ltd.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHZ2300416 | Import re-registration | 2023/11/02 | Merck Sharp & Dohme B.V.; Alkermes Pharma Ireland Ltd.; MSD R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 3 records · Latest accepted 2023/08/23
Import re-registration · 1Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300346 | Import re-registration | 2023/08/23 | Merck Sharp & Dohme B.V.; MSD International GmbH; MSD R&D (China) Co. Ltd | CDE ↗ |
| JYHB2101233 | Supplement | 2021/07/05 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
| JYHB2101048 | Supplement | 2021/04/15 | Merck Sharp & Dohme B.V.; MSD International GmbH | CDE ↗ |
No verified English name 2 records · Latest accepted 2023/07/12
Import · 2
Rocuronium Bromide Injection 3 records · Latest accepted 2023/03/24
Import re-registration · 1Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300169 | Import re-registration | 2023/03/24 | Merck Sharp & Dohme B.V.; Siegfried Hameln GmbH; MSD R&D (China) Co. Ltd. | CDE ↗ |
| JYHB2200437 | Supplement | 2022/08/11 | Merck Sharp & Dohme B.V.; Siegfried Hameln GmbH | CDE ↗ |
| JYHB2101396 | Supplement | 2021/09/13 | Merck Sharp & Dohme B. V.; Siegfried Hameln GmbH | CDE ↗ |
No verified English name 2 records · Latest accepted 2022/08/23
Supplement · 2
Posaconazole Oral Suspension 3 records · Latest accepted 2022/08/11
Import re-registration · 1Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2200210 | Import re-registration | 2022/08/11 | Merck Sharp & Dohme B.V.; Patheon Inc. Whitby Operations; Name not romanized | CDE ↗ |
| JYHB2200285 | Supplement | 2022/06/09 | Merck Sharp & Dohme B.V.; Patheon Inc. Whitby Operations | CDE ↗ |
| JYHB2101240 | Supplement | 2021/07/08 | Merck Sharp & Dohme B.V.; Patheon Inc. Whitby Operations | CDE ↗ |
Elbasvir and Grazoprevir Tablets 1 records · Latest accepted 2022/06/22
Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2200160 | Import re-registration | 2022/06/22 | Merck Sharp & Dohme B.V.; MSD International GmbH; MSD R&D(China) Co. Ltd | CDE ↗ |
Ezetimibe and Simvastatin Tablets 1 records · Latest accepted 2022/01/13
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2200020 | Supplement | 2022/01/13 | Merck Sharp & Dohme B.V.; MSD INTERNATIONAL GMBH (SINGAPORE BRANCH) | CDE ↗ |
No verified English name 2 records · Latest accepted 2021/12/08
Supplement · 2
Simvastatin Tablets 4 records · Latest accepted 2021/11/29
Supplement · 2Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2101560 | Supplement | 2021/11/29 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited | CDE ↗ |
| JYHB2101559 | Supplement | 2021/11/29 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited | CDE ↗ |
| JYHZ2100695 | Import re-registration | 2021/11/12 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited; Organon (Shanghai) Pharmaceutical Technology Co. Ltd. | CDE ↗ |
| JYHZ2100627 | Import re-registration | 2021/11/12 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited; Organon (Shanghai) Pharmaceutical Technology Co. Ltd. | CDE ↗ |
Ganirelix Injection 2 records · Latest accepted 2021/08/16
Supplement · 2
Losartan Potassium and Hydrochlorothiazide Tablets 2 records · Latest accepted 2021/08/03
Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2100581 | Import re-registration | 2021/08/03 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited; Organon (Shanghai) Pharmaceutical Technology Co. Ltd. | CDE ↗ |
| JYHZ2100580 | Import re-registration | 2021/08/03 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme Limited; Organon (Shanghai) Pharmaceutical Technology Co. Ltd. | CDE ↗ |
Ezetimibe and Atorvastatin Calcium Trihydrate Tablets 2 records · Latest accepted 2021/06/07
Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2101018 | Import | 2021/06/07 | Merck Sharp & Dohme B.V.; MSD International GmbH (Puerto Rico Branch) LLC | CDE ↗ |
| JXHS2101017 | Import | 2021/06/07 | Merck Sharp & Dohme B.V.; MSD International GmbH (Puerto Rico Branch) LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
Changes in the last 90 days
11 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.
This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 9 applicationsNo longer listed under review: 2 applications
- 2026/11/09Accepted
No verified English name
JXSS2600104
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ - 2026/11/09Accepted
No verified English name
JXSS2600103
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ - 2026/11/04Accepted
No verified English name
JYHB2600596
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗ - 2026/11/04Accepted
No verified English name
JYHB2600595
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗ - 2026/10/24No longer listed under review
No verified English name
JXSS2500150
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2025/12/10
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/24No longer listed under review
No verified English name
JXSS2500149
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2025/12/10
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/20Accepted
Sugammadex Sodium Injection
JYHZ2600271
Fact date: 2026/10/20 · Site observation date: 2026/10/22
View source ↗ - 2026/10/20Accepted
Sugammadex Sodium Injection
JYHZ2600270
Fact date: 2026/10/20 · Site observation date: 2026/10/22
View source ↗ - 2026/09/17Accepted
No verified English name
JTS2600144
Fact date: 2026/09/17 · Site observation date: 2026/10/22
View source ↗ - 2026/08/19Accepted
No verified English name
JXSS2600075
Fact date: 2026/08/19 · Site observation date: 2026/10/22
View source ↗ - 2026/08/19Accepted
No verified English name
JXSS2600074
Fact date: 2026/08/19 · Site observation date: 2026/10/22
View source ↗
Under review
26 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JXSS2600104 | Import | 2026/11/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2600103 | Import | 2026/11/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2600596 | Supplement | 2026/11/04 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| No verified English name | JYHB2600595 | Supplement | 2026/11/04 | Merck Sharp & Dohme B.V.; FAREVA Mirabel | CDE ↗ |
| Sugammadex Sodium Injection | JYHZ2600271 | Import re-registration | 2026/10/20 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
| Sugammadex Sodium Injection | JYHZ2600270 | Import re-registration | 2026/10/20 | Merck Sharp & Dohme B.V.; Patheon Manufacturing Services LLC; MSD R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2600075 | Import | 2026/08/19 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600074 | Import | 2026/08/19 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| Caspofungin Acetate for Injection | JYHZ2600185 | Import re-registration | 2026/08/03 | Merck Sharp & Dohme B. V.; FAREVA Mirabel | CDE ↗ |
| Sugammadex Sodium Injection | JYHB2600367 | Supplement | 2026/07/02 | Merck Sharp & Dohme B.V.; N.V. Organon | CDE ↗ |
| No verified English name | JXSS2600053 | Import | 2026/06/16 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600052 | Import | 2026/06/16 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600047 | Import | 2026/06/04 | Merck Sharp & Dohme B. V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Lt d | CDE ↗ |
| No verified English name | JXSS2600046 | Import | 2026/06/04 | Merck Sharp & Dohme B. V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Lt d | CDE ↗ |
| No verified English name | JXSS2600033 | Import | 2026/04/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600032 | Import | 2026/04/09 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D（China）Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600031 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600030 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600029 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600028 | Import | 2026/04/04 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600027 | Import | 2026/04/02 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S. p. A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600026 | Import | 2026/04/02 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600022 | Import | 2026/03/14 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JXSS2600021 | Import | 2026/03/14 | Merck Sharp & Dohme B.V.; BSP Pharmaceuticals S.p.A.; MSD R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JYHB2500658 | Supplement | 2025/12/03 | Merck Sharp & Dohme B.V.; Merck Sharp & Dohme LLC; ACS DOBFAR S.P.A. | CDE ↗ |
| No verified English name | JYHB2500269 | Supplement | 2025/05/15 | Merck Sharp & Dohme B.V.; Steri-Pharma LLC | CDE ↗ |
Catalogue holder records
10 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets | Merck Sharp & Dohme B.V. | MSD International GmbH | 国药准字HJ20200066 | 2020/12/29 | Imported originator drug | CDE ↗ |
| Doravirine Tablets | Merck Sharp & Dohme B.V. | MSD International GmbH | 国药准字HJ20200050 | 2020/11/24 | Imported originator drug | CDE ↗ |
| Losartan Potassium and Hydrochlorothiazide Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Limited | H20181181; H20181182 | 2010/03/26 | Imported originator drug | CDE ↗ |
| Etoricoxib Tablets | Merck Sharp & Dohme B.V. | Frosst Iberica SA | H20181027 | 2007/05/21 | Imported originator drug | CDE ↗ |
| Etoricoxib Tablets | Merck Sharp & Dohme B.V. | Frosst Iberica SA | H20181029 | 2007/05/21 | Imported originator drug | CDE ↗ |
| Simvastatin Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Limited | H20160429 | 2002/01/25 | Imported originator drug | CDE ↗ |
| Montelukast Sodium Chewable Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Ltd. | H20160440 | 2001/07/12 | Imported originator drug | CDE ↗ |
| Losartan Potassium and Hydrochlorothiazide Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Limited | H20171067;H20171073 | 2000/06/16 | Imported originator drug | CDE ↗ |
| Montelukast Sodium Chewable Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Ltd. | H20160441 | 1999/11/20 | Imported originator drug | CDE ↗ |
| Simvastatin Tablets | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme Limited | H20130146 | 1992/08/31 | Imported originator drug | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
10 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JTH2600128 | Not stated by source | 2026/07/03 | Steri-Pharma LLC; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Doravirine Tablets | JTH2600091 | Not stated by source | 2026/05/08 | MSD International GmbH; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Sugammadex Sodium Injection | JTH2600069 | Not stated by source | 2026/03/31 | N.V. Organon; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2500162 | Not stated by source | 2025/10/29 | Merck Sharp & Dohme LLC; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2500161 | Not stated by source | 2025/10/29 | ACS DOBFAR S.P.A.; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2500009 | Not stated by source | 2025/01/25 | BSP Pharmaceuticals S.p.A.; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2500008 | Not stated by source | 2025/01/25 | BSP Pharmaceuticals S.p.A.; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2500007 | Not stated by source | 2025/01/25 | Boehringer Ingelheim (BIB); Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300101 | Not stated by source | 2023/04/14 | Steri-Pharma LLC.; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300060 | Not stated by source | 2023/03/01 | Merck Sharp & Dohme LLC; Merck Sharp & Dohme B.V.; Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/11 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/11 06:38
- Full API register
- Last successful update: 2026/11/11 06:40
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete
First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.